BiotechTube

Pembrolizumab + Defactinib

Phase 1Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malignant Pleural Mesothelioma

Conditions

Malignant Pleural Mesothelioma

Trial Timeline

Sep 1, 2020 → Dec 31, 2022

NCT ID
NCT04201145

About Pembrolizumab + Defactinib

Pembrolizumab + Defactinib is a phase 1 stage product being developed by Merck for Malignant Pleural Mesothelioma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04201145. Target conditions include Malignant Pleural Mesothelioma.

What happened to similar drugs?

5 of 20 similar drugs in Malignant Pleural Mesothelioma were approved

Approved (5) Terminated (2) Active (13)
✅Deep Neuromuscular Blockade (NMB) + Moderate Neuromuscular Blockade (NMB) + Sugammadex + NeostigmineMerckApproved
✅Rocuronium + Sugammadex + Neostigmine + GlycopyrrolateMerckApproved
✅ZelborafRocheApproved
✅Atezolizumab Injection [Tecentriq]RocheApproved
✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04201145Phase 1Withdrawn
NCT03727880Phase 2Completed

Competing Products

20 competing products in Malignant Pleural Mesothelioma

See all competitors
ProductCompanyStageHype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabCSPC Pharmaceutical Group LimitedPhase 1/2
39
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Tadalafil + GemcitabineEli LillyPhase 1
29
Patritumab DeruxtecanDaiichi SankyoPhase 1/2
39
Tivantinib + FOLFOXDaiichi SankyoPhase 1/2
32
DS-1123Daiichi SankyoPhase 1
29
DS-8201aDaiichi SankyoPhase 1
29
DS-5573aDaiichi SankyoPhase 1
21
DS-6051bDaiichi SankyoPhase 1
29
U3-1565Daiichi SankyoPhase 1
29
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue MedicationsDaiichi SankyoPhase 1/2
39
DS-3201b + DS-3201bDaiichi SankyoPhase 1
33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kgDaiichi SankyoPhase 1
29
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
39
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
39
CP-461Astellas PharmaPhase 2
27
enfortumab vedotinAstellas PharmaPhase 1
29
LNF1901 Monoclonal Antibody InjectionSun PharmaceuticalPhase 1
36
Perampanel + Standard of CareEisaiPhase 1/2
32
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
40